Full Alliance Group Obtains FDA MOCRA Registration for HOCl Platform
Full Alliance Group (OTC: FAGI) and its 51% owned subsidiary, Aquaox Pure Solutions, have achieved two major regulatory milestones in the hypochlorous acid (HOCl) industry. The company has successfully completed Human Repeat Insult Patch Testing (RIPT) for its HOCl Hydrogel and obtained FDA MOCRA registration for its HOCl platform.
The company's proprietary nanobubble HOCl technology targets three key markets: the $13.2B clean beauty market growing at 9.7% CAGR, the e-commerce beauty sector where 67% of purchases are influenced by social media, and the $4.2B infection prevention market. Through its flagship product JusSpray鈩�, FAGI demonstrates consumer acceptance of HOCl formulations while establishing direct-to-consumer capabilities.
The company's vertically integrated approach encompasses proprietary technology, FDA-compliant manufacturing, and direct consumer sales, positioning it as a turnkey partner for private-label brands and healthcare entrepreneurs.
Full Alliance Group (OTC: FAGI) e la sua controllata al 51%, Aquaox Pure Solutions, hanno raggiunto due importanti traguardi normativi nel settore dell'acido ipocloroso (HOCl). L'azienda ha completato con successo il Human Repeat Insult Patch Testing (RIPT) per il suo Hydrogel a base di HOCl e ha ottenuto la registrazione FDA MOCRA per la sua piattaforma HOCl.
La tecnologia proprietaria a nanobolle di HOCl dell'azienda si rivolge a tre mercati chiave: il mercato della bellezza pulita da 13,2 miliardi di dollari in crescita con un CAGR del 9,7%, il settore della bellezza e-commerce dove il 67% degli acquisti 猫 influenzato dai social media, e il mercato della prevenzione delle infezioni da 4,2 miliardi di dollari. Attraverso il suo prodotto di punta JusSpray鈩�, FAGI dimostra l'accettazione da parte dei consumatori delle formulazioni a base di HOCl, consolidando al contempo capacit脿 di vendita diretta al consumatore.
L'approccio integrato verticalmente dell'azienda comprende tecnologia proprietaria, produzione conforme alle normative FDA e vendite dirette al consumatore, posizionandola come partner chiavi in mano per marchi private label e imprenditori nel settore sanitario.
Full Alliance Group (OTC: FAGI) y su subsidiaria con el 51% de propiedad, Aquaox Pure Solutions, han alcanzado dos hitos regulatorios importantes en la industria del 谩cido hipocloroso (HOCl). La compa帽铆a ha completado con 茅xito las pruebas de parche de irritaci贸n repetida humana (RIPT) para su hidrogel de HOCl y ha obtenido la registro FDA MOCRA para su plataforma HOCl.
La tecnolog铆a propietaria de nanoburbujas de HOCl de la empresa apunta a tres mercados clave: el mercado de belleza limpia de 13.2 mil millones de d贸lares que crece a una tasa compuesta anual del 9.7%, el sector de belleza en comercio electr贸nico donde el 67% de las compras est谩n influenciadas por las redes sociales, y el mercado de prevenci贸n de infecciones de 4.2 mil millones de d贸lares. A trav茅s de su producto estrella JusSpray鈩�, FAGI demuestra la aceptaci贸n del consumidor hacia las formulaciones de HOCl mientras establece capacidades de venta directa al consumidor.
El enfoque verticalmente integrado de la empresa abarca tecnolog铆a propietaria, fabricaci贸n conforme a la FDA y ventas directas al consumidor, posicion谩ndola como un socio llave en mano para marcas privadas y emprendedores en el sector de la salud.
Full Alliance Group (OTC: FAGI)鞕� 51% 歆�攵勳潉 氤挫湢頃� 鞛愴殞靷� Aquaox Pure Solutions臧� 彀晞鞐检唽靷�(HOCl) 靷办梾鞐愳劀 霊� 臧�歆� 欤检殧 攴滌牅 靹标臣毳� 雼劚頄堨姷雼堧嫟. 須岇偓電� HOCl 頃橃澊霌滊瓴旍棎 雽�頃� 鞚戈皠 氚橂车 鞛愱饭 韺箻 韰岇姢韸�(RIPT)毳� 靹标车鞝侅溂搿� 鞕勲頄堨溂氅�, HOCl 頂岆灚韽检棎 雽�頃� FDA MOCRA 霌彪鞚� 須嶋摑頄堨姷雼堧嫟.
須岇偓鞚� 霃呾瀽鞝侅澑 雮橂吀氩勲笖 HOCl 旮办垹鞚� 靹� 臧�歆� 欤检殧 鞁滌灔鞚� 瓴儱頃╇媹雼�: 鞐绊弶攴� 靹膘灔毳� 9.7%搿� 靹膘灔 欷戩澑 132鞏� 雼煬 攴滊鞚� 韥措Π 敕绊嫲 鞁滌灔, 67%鞚� 甑Г臧� 靻岇厹 氙鸽敂鞏挫潣 鞓來枼鞚� 氚涬姅 鞝勳瀽靸侁卑霝� 敕绊嫲 攵�氍�, 攴鸽Μ瓿� 42鞏� 雼煬 攴滊鞚� 臧愳椉 鞓堧癌 鞁滌灔鞛呺媹雼�. 雽�響� 鞝滍拡鞚� JusSpray鈩㈦ゼ 韱淀暣 FAGI電� HOCl 鞝滍槙鞐� 雽�頃� 靻岆箘鞛� 靾橃毄鞚� 鞛呾頃橂┌ 歆侅爲 靻岆箘鞛� 韺愲Г 鞐焿鞚� 甑稌頃橁碃 鞛堨姷雼堧嫟.
須岇偓鞚� 靾橃 韱淀暕 鞝戧芳氩曥潃 霃呾瀽 旮办垹, FDA 攴滌爼 欷�靾� 鞝滌“, 歆侅爲 靻岆箘鞛� 韺愲Г毳� 韽暔頃橂┌, 鞚措ゼ 韱淀暣 頂勲澕鞚措箺 霛茧波 敫岆灉霌� 氚� 項姢旒�鞏� 彀届梾鞛愲摛鞐愱矊 韯错偆 韺岉姼雱堧 鞛愲Μ毵り箑頃橁碃 鞛堨姷雼堧嫟.
Full Alliance Group (OTC : FAGI) et sa filiale d茅tenue 脿 51 %, Aquaox Pure Solutions, ont franchi deux 茅tapes r茅glementaires majeures dans l'industrie de l'acide hypochloreux (HOCl). L'entreprise a r茅ussi le Human Repeat Insult Patch Testing (RIPT) pour son hydrogel HOCl et a obtenu l'enregistrement FDA MOCRA pour sa plateforme HOCl.
La technologie propri茅taire de nanobulles HOCl de la soci茅t茅 cible trois march茅s cl茅s : le march茅 de la beaut茅 propre de 13,2 milliards de dollars en croissance 脿 un TCAC de 9,7 %, le secteur de la beaut茅 en e-commerce o霉 67 % des achats sont influenc茅s par les r茅seaux sociaux, et le march茅 de la pr茅vention des infections de 4,2 milliards de dollars. Gr芒ce 脿 son produit phare JusSpray鈩�, FAGI d茅montre l'acceptation des formulations HOCl par les consommateurs tout en 茅tablissant des capacit茅s de vente directe aux consommateurs.
L'approche verticalement int茅gr茅e de l'entreprise englobe la technologie propri茅taire, la fabrication conforme 脿 la FDA et la vente directe aux consommateurs, la positionnant comme un partenaire cl茅 en main pour les marques en marque blanche et les entrepreneurs du secteur de la sant茅.
Full Alliance Group (OTC: FAGI) und seine zu 51 % gehaltene Tochtergesellschaft Aquaox Pure Solutions haben zwei bedeutende regulatorische Meilensteine in der Hypochlors盲ure (HOCl)-Branche erreicht. Das Unternehmen hat erfolgreich Human Repeat Insult Patch Testing (RIPT) f眉r sein HOCl-Hydrogel abgeschlossen und die FDA MOCRA-Registrierung f眉r seine HOCl-Plattform erhalten.
Die firmeneigene Nanobubble-HOCl-Technologie zielt auf drei Schl眉sselm盲rkte ab: den 13,2 Milliarden Dollar gro脽en Clean-Beauty-Markt mit einem CAGR von 9,7 %, den E-Commerce-Sch枚nheitssektor, in dem 67 % der K盲ufe von sozialen Medien beeinflusst werden, und den 4,2 Milliarden Dollar gro脽en Markt f眉r Infektionspr盲vention. Mit seinem Flaggschiffprodukt JusSpray鈩� zeigt FAGI die Akzeptanz von HOCl-Formulierungen bei Verbrauchern und baut gleichzeitig Direktvertriebsf盲higkeiten auf.
Der vertikal integrierte Ansatz des Unternehmens umfasst firmeneigene Technologie, FDA-konforme Herstellung und Direktvertrieb an Verbraucher und positioniert es als schl眉sselfertigen Partner f眉r Private-Label-Marken und Unternehmer im Gesundheitswesen.
- Obtained FDA MOCRA registration, enabling market access through major retail channels
- Successful completion of RIPT testing for HOCl Hydrogel validates product safety
- Targeting $13.2B clean beauty market with 9.7% CAGR
- Vertically integrated business model from manufacturing to direct sales
- Proprietary nanobubble technology addresses industry challenges like product stability
- Operating in a highly competitive market with established players
- Regulatory compliance requirements could impact expansion costs
- Dependent on consumer adoption of HOCl as alternative to traditional products
Achieves critical regulatory milestones, positioning company as leading turnkey partner in booming hypochlorous acid sector to capture portion of growing
TAMPA, Fla., July 11, 2025 (GLOBE NEWSWIRE) -- Full Alliance Group Inc. (OTC: FAGI) and its fifty one percent owned subsidiary, Aquaox Pure Solutions, LLC, announce two pivotal regulatory achievements that position the company at the forefront of the rapidly expanding hypochlorous acid (HOCl) industry.
Market Timing Meets Regulatory Excellence
The successful completion of third-party Human Repeat Insult Patch Testing (RIPT) for Aquaox's HOCl Hydrogel and FDA MOCRA registration for Aquaox's HOCl arrives as consumer demand for science-backed, non-toxic personal care solutions reaches unprecedented levels. With
"We're not just responding to market trends鈥攚e're helping define them," said Michel Van Schaik, President of Aquaox Pure Solutions. "While competitors struggle with regulatory compliance and formulation challenges, we've built a platform that delivers both safety and scalability in a market hungry for clean solutions."
Disrupting Traditional Categories Through Innovation
Aquaox's FDA MOCRA registration positions the company as a rare turnkey partner capable of supporting private-label brands and healthcare entrepreneurs entering regulated retail channels including Amazon, TikTok Shop, grocery, chain pharmacies and other big box retailers. This regulatory advantage creates significant barriers for competitors while opening lucrative distribution partnerships in a market where compliance increasingly determines market access.
The company's proprietary nanobubble HOCl technology addresses critical industry pain points including product stability, shelf-life limitations, and manufacturing consistency鈥攃hallenges that have historically prevented widespread HOCl adoption despite growing consumer awareness of its benefits.
Capturing Multiple High-Growth Verticals
Aquaox's platform strategy targets three converging market opportunities:
Clean Beauty & Personal Care: The
E-commerce & Digital-First Brands: With
Healthcare & Clinical Applications: The
JusSpray鈩�: Consumer Market Validation
The company's flagship consumer product, JusSpray鈩� (www.jusspray.com), serves as both revenue generator and market proof-of-concept. This alcohol-free, fragrance-free HOCl spray demonstrates consumer acceptance of advanced hypochlorous formulations while establishing Aquaox's direct-to-consumer capabilities.
"JusSpray鈩� isn't just a product鈥攊t's validation that consumers are ready for science-backed alternatives to traditional sanitizers and skin care products," added Van Schaik. "Every bottle sold proves our manufacturing quality and market positioning."
Competitive Moat Through Vertical Integration
Unlike competitors focused solely on manufacturing or retail, Aquaox's vertically integrated approach鈥攆rom proprietary nanobubble technology through FDA-compliant manufacturing to direct consumer sales鈥攃reates multiple revenue streams and competitive advantages:
- Technology Leadership: Nanobubble enhancement delivers superior product performance and stability
- Regulatory Expertise: FDA MOCRA registration enables rapid market entry for partners
- Manufacturing Scale: GMP-compliant facility supports both bulk and private-label production
- Market Validation: Direct consumer sales through JusSpray鈩� demonstrate market acceptance
Industry Leadership in Emerging Category
As traditional antiseptic and personal care companies face increasing regulatory scrutiny and consumer backlash against harsh chemicals, Aquaox has positioned itself as the category leader in next-generation HOCl solutions. The company's comprehensive platform addresses every aspect of the value chain, from technology development through regulatory compliance to market distribution.
"We're not just building a product company鈥攚e're building the infrastructure for an entire category," said Van Schaik. "While others focus on individual products, we're creating the platform that enables the whole HOCl market to scale."
About the Growing HOCl Market
Hypochlorous acid represents one of the fastest-growing segments in both personal care and healthcare, driven by increasing consumer awareness of its safety profile and efficacy. Unlike traditional antiseptics, HOCl is naturally produced by white blood cells and breaks down into salt and water, making it ideal for sensitive skin applications and frequent use scenarios.
Cognitive Market Research estimates the HOCl the 2025 Market size to be US聽
Investment Positioning
Full Alliance Group's investment in Aquaox Pure Solutions represents a strategic play on multiple converging trends: clean beauty adoption, regulatory tightening in personal care, and the shift toward science-backed wellness solutions. The company's early-mover advantage in FDA-compliant HOCl manufacturing positions it to capture significant market share as the category matures.
About Aquaox Pure Solutions, LLC Aquaox Pure Solutions is the leading advanced hypochlorous acid manufacturing platform, specializing in ultra-pure, shelf-stable, and clinically validated HOCl solutions. Through proprietary nanobubble technology and GMP-compliant infrastructure, Aquaox serves the growing demand for clean, effective alternatives across medical, consumer, and industrial markets.
About Full Alliance Group, Inc. (OTC: FAGI) Full Alliance Group is a diversified holding company focused on scaling high-growth businesses in health, science, and sustainability. Through strategic subsidiaries including Aquaox Pure Solutions, Full Alliance builds market-leading platforms that capitalize on emerging consumer trends while delivering sustainable shareholder value.
Investor & Media Contact:
Investor Relations [email protected]
www.fullalliance-group.com
Consumer Product: www.tryjusspray.com
B2B Manufacturing:
This press release contains forward-looking statements. Market data sourced from industry research reports and company analysis.
Media Contact:
Full Alliance Group Inc. Investor Relations
Gabe Rodriguez, Erelations Group
[email protected]
(623) 261-9046
Pure Aquaox Solutions, LLC
Brett Phillips
(800) 895-4415
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact are forward-looking statements, including but not limited to statements regarding future financial performance, business strategy, and plans and objectives for future operations. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied by such forward-looking statements.
A photo accompanying this announcement is available at
FAQ
What regulatory approvals did Full Alliance Group (FAGI) receive for its HOCl platform?
What markets is Full Alliance Group (FAGI) targeting with its HOCl technology?
What is JusSpray and how does it fit into FAGI's business strategy?
How does Full Alliance Group's vertically integrated approach provide competitive advantages?
What percentage of beauty purchases are influenced by social media according to FAGI?
